Results 91 to 100 of about 644,957 (254)

A Three-Dimensional Culture-Drug Sensitivity Test Predicts MDM2 Inhibitor-Sensitivity in SMARCB1/INI1-Deficient Tumors. [PDF]

Cancer Sci
This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Goto H, Nishime C, Ohtsu T, Ito M, Sagisaka M, Naruto T, Kitagawa N, Tanaka M, Yanagimachi M, Hiroshima Y, Takita J, Hayashi Y, Miyagi Y.   +12 more
europepmc   +2 more sources

Proto‐Panic Modulation by Caffeine‐Proteinoid Complexes

Journal of Applied Polymer Science, EarlyView.
Caffeine–proteinoid microspheres synthesized by thermal polymerization exhibit compartmentalized drug loading with encapsulation efficiencies of 61%–82% and triphasic release kinetics. Electrochemical monitoring reveals multi‐scale oscillatory dynamics consistent with chaotic and damped harmonic behavior, while Boolean logic operations demonstrate ...
Panagiotis Mougkogiannis, Andrew Adamatzky   +1 more
wiley   +1 more source

MDM2: current research status and prospects of tumor treatment

Cancer Cell International
Mousedouble minute 2 (MDM2) is one of the molecules activated by p53 and plays an important role in the regulation of p53. MDM2 is generally believed to function as a negative regulator of p53 by facilitating its ubiquitination and subsequent degradation.
Yumei Yao, Qian Zhang, Zhi Li, Hushan Zhang   +3 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance

Genes and Diseases, 2019
Overexpression of the MDM2 oncogene and mutations in the p53 tumor suppressor commonly occur in hepatocellular carcinoma (HCC) and are associated with increased mortality due to this disease.
Wei Wang, Bo Hu, Jiang-Jiang Qin, Jian-Wen Cheng, Xin Li, Mehrdad Rajaei, Jia Fan, Xin-Rong Yang, Ruiwen Zhang   +8 more
doaj   +1 more source

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

, 2015
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&
Favre L, Pujals A, Wiels J, Gaulard P
core  

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, EarlyView.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis

Oncology Reviews
Many drugs currently used in cancer chemotherapy exert their toxic action mainly by inhibiting ribosome biogenesis (RiBi). This is due to the fact that after inhibition of rRNA transcription ribosomal proteins, no longer used for ribosome building, bind ...
Davide Treré, Davide Treré, Lorenzo Montanaro, Lorenzo Montanaro, Massimo Derenzini, Claudio Agostinelli, Claudio Agostinelli, Enrico Derenzini, Enrico Derenzini   +8 more
doaj   +1 more source

Clinical overview of MDM2/X targeted therapies

Frontiers in Oncology, 2016
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions, maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation, and inhibiting its transcriptional activity.
Andrew eBurgess, Andrew eBurgess, Kee Ming Chia, Sue eHaupt, David eThomas, David eThomas, Ygal eHaupt, Elgene eLim, Elgene eLim   +8 more
doaj   +1 more source